Identification of potent tricyclic prodrug S1P1 receptor modulators

Recently, our research group reported the identification of prodrug amino-alcohol 2 as a potent and efficacious S1P1 receptor modulator. This molecule is differentiated preclinically over the marketed drug fingolimod (Gilenya 1), whose active phosphate metabolite is an S1P1 full agonist, in terms of...

Full description

Saved in:
Bibliographic Details
Published in:MedChemComm 2017-04, Vol.8 (4), p.725-729
Main Authors: Marcoux, David, Xiao, Hai-Yun, Murali Dhar, TG, Xie, Jenny, Lehman-McKeeman, Lois D, Wu, Dauh-Rurng, Dabros, Marta, Yang, Xiaoxia, Taylor, Tracy L, Zhou, Xia D, Heimrich, Elizabeth M, Thomas, Rochelle, McIntyre, Kim W, Shi, Hong, Levesque, Paul C, Sun, Huadong, Yang, Zheng, Marino, Anthony M, Cornelius, Georgia, D'Arienzo, Celia J, Gupta, Anuradha, Pragalathan, Bala, Rampulla, Richard, Mathur, Arvind, Shen, Ding Ren, Cvijic, Mary Ellen, Salter-Cid, Luisa, Lombardo, Louis J, Carter, Percy H, Dyckman, Alaric J
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, our research group reported the identification of prodrug amino-alcohol 2 as a potent and efficacious S1P1 receptor modulator. This molecule is differentiated preclinically over the marketed drug fingolimod (Gilenya 1), whose active phosphate metabolite is an S1P1 full agonist, in terms of pulmonary and cardiovascular safety. S1P1 partial agonist 2, however, has a long half-life in rodents and was projected to have a long half-life in humans. The purpose of this communication is to disclose highly potent partial agonists of S1P1 with shorter half-lives relative to the clinical compound 2. PK/PD relationships as well as their preclinical pulmonary and cardiovascular safety assessment are discussed.
ISSN:2040-2503
2040-2511
DOI:10.1039/c6md00539j